ExpreS2ion Biotech advances breast cancer project with rights issue of SEK 53 million

About this update from Expres2ion Biotech Holding Ab

ExpreS2ion Biotech is in an exciting phase following positive Phase I data for the breast cancer candidate ES2B-C001. With a successful evaluation behind it, the company is now preparing the next step for the project, while continuing to drive the rest of the pipeline and the ExpreS2 platform. To finance the continued development, the company is carrying out a rights issue of units of approximately SEK 53 million . CEO Bent U. Frandsen visited BioStock to tell more about the company's partner strategy, expected milestones in the next 12 to 18 months and how the new capital will primarily be allocated. See the full interview at biostock.se: https://biostock.se/en/2026/04/expres2ion-biotech-avancerar-brostcancerprojekt-med-foretradesemission-om-53-mkr/ This is a press release from  BioStock - Connecting Innovation & Capital .  https://www.biostock.se Follow BioStock Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter  Follow BioStock on social media: LinkedIn and Facebook!     About BioStock   BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.   BioStock – Connecting Innovation & Capital.  © Modular Finance, source Nordic Press Releases

View stock analysis, news, and events for Expres2ion Biotech Holding Ab